Everolimus Versus Sunitinib in Non-Clear Cell Renal Cell Carcinoma

Model scores of the 29,894 trials active now.

Model score 23% for any early termination, 16% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (3,728 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2019-09-09. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: carcinomacellheartsurgeryinjury
  Phrases that lowered it: patients whosafety ofdrugsfastingcorticosteroids
• Design: crossover (lowers risk) · Design
• Sponsor's past termination rate: 27.8% (raises risk) · Sponsor's track record
• Phase: 2 (raises risk) · Design
• Accepts healthy volunteers: No (raises risk) · Who can join
• Disease area, cancer: Yes (raises risk) · Disease area
• Has a data monitoring committee: Yes (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 148 (lowers risk) · Sponsor's track record
• Sponsor's past trials: 248 (lowers risk) · Sponsor's track record
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Drug's FAERS reports with a death: 26.2% (raises risk) · Drug's FDA history
• Minimum age: 18 (raises risk) · Who can join
• Maximum age: not given (raises risk) · Who can join
• Keywords listed: 13 (raises risk) · Design
• Drug's FAERS reports marked serious: 93.7% (raises risk) · Drug's FDA history
• Drug's FAERS reports before start: 7045 (raises risk) · Drug's FDA history
• Primary purpose: treatment (raises risk) · Design
• Collaborators: 1 (raises risk) · Design
• Disease area, neurology: No (lowers risk) · Disease area
• Disease area, urogenital: Yes (raises risk) · Disease area

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Everolimus as Second-line Therapy in Metastatic Renal Cell Carcinoma NCT01491672 · started 2011 · scored riskier than 72% of active trials completed
• Everolimus and Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma (RCC) NCT01399918 · started 2011 · scored riskier than 52% of active trials completed
• Sunitinib Plus Temsirolimus in Patients With Renal Cell Cancer (RCC) NCT01122615 · started 2010 · scored riskier than 94% of active trials completed
• Phase II Study of Afinitor vs. Sutent in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma NCT01108445 · started 2010 · scored riskier than 95% of active trials completed
• A Study Comparing AZD2014 vs Everolimus in Patients With Metastatic Renal Cancer NCT01793636 · started 2013 · scored riskier than 88% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.